Date: 2013-09-18
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the study
Company: GW Pharmaceuticals (UK)
Product: GWP42006
Action
mechanism: GWP42006 is a non-psychoactive cannabinoid extracted from specific chemotypes of the cannabis plant which has shown the ability to treat seizures in pre-clinical models of epilepsy with significantly fewer side effects than currently approved anti-epileptic drugs.
Disease: epilepsy
Therapeutic area: CNS diseases - Neurological diseases
Country:
Trial details:
Latest
news: * On September 18, 2013, GW Pharmaceuticals has announced that it has commenced a Phase 1 clinical trial of product candidate GWP42006 for the treatment of epilepsy.
